Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients
Public ClinicalTrials.gov record NCT00124449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess if Abatacept given for six months will prevent rheumatoid arthritis (RA) in patients who are at risk for the development of RA in comparison to placebo. High risk patients are defined as those having a positive laboratory test for anti-cyclic citrullinated peptide (anti-CCP2).
Study identification
- NCT ID
- NCT00124449
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2005
- Primary completion
- Apr 30, 2007
- Completion
- Mar 31, 2008
- Last update posted
- Apr 6, 2015
2005 – 2008
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Huntsville | Alabama | — | — |
| Local Institution | Mobile | Alabama | — | — |
| Local Institution | Huntington Beach | California | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | Boulder | Colorado | — | — |
| Local Institution | Colorado Springs | Colorado | — | — |
| Local Institution | Fort Lauderdale | Florida | — | — |
| Local Institution | Chicago | Illinois | — | — |
| Local Institution | Evansville | Indiana | — | — |
| Local Institution | New Orleans | Louisiana | — | — |
| Local Institution | Cumberland | Maryland | — | — |
| Local Institution | Hagerstown | Maryland | — | — |
| Local Institution | Duluth | Minnesota | — | — |
| Local Institution | Durham | North Carolina | — | — |
| Local Institution | Wilmington | North Carolina | — | — |
| Local Institution | Oklahoma City | Oklahoma | — | — |
| Local Institution | Willow Grove | Pennsylvania | — | — |
| Local Institution | Charleston | South Carolina | — | — |
| Local Institution | Austin | Texas | — | — |
| Local Institution | Arlington | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00124449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2015 · Synced Sep 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00124449 live on ClinicalTrials.gov.